Acriva UD Reviol multifocal intraocular lens in patients undergoing cataract surgery--6-month follow-up.
To evaluate visual outcomes and complications in patients after binocular Acriva UD Reviol MFB 625 (VSY Biotechnology) multifocal intraocular lens implantation. 40 eyes of 20 patients were reassessed at six months following bilateral IOL implantation. The following were evaluated: binocular UDVA and near, binocular uncorrected intermediate visual acuity, spectacle independence, uncorrected binocular photopic contrast sensitivity for distance and near, uncorrected binocular mesopic contrast sensitivity for distance (CS-CSV-1000, F.A.C.T.); stereoscopic vision (Lang Stereotest II), patient satisfaction, subjective symptoms (modified NE VFQ-25) and postoperative complications. Six months after surgery the mean binocular UDVA was logMAR -0.05 ± 0.07, UIVA was +0.04 ± 0.09 and uncorrected near visual acuity was +0.06 ± 0.08. At six months postoperatively, all patients were totally spectacle-independent. Contrast sensitivity under different conditions was within the normal range at all spacial frequencies. Stereoscopic vision was normal in all patients. Low level of glare/halo perception was detected in 55% of patients. General vision quality was high and rated as 1.85 (1--the best, 5--the worst). No severe postoperative complications were observed. Cataract surgery with Acriva UD Reviol MFB 625 implantation in a selected group of patients was very effective for all distances and provided excellent patient satisfaction.